Biodexa Pharmaceuticals (BDRX) Gross Margin (2015 - 2016)
Biodexa Pharmaceuticals (BDRX) reported Gross Margin of 168.39% for Q4 2016, up 7885.0% on a YoY basis from 2.11% in Q1 2016, and up 88.06% sequentially from 89.54% in Q4 2015.
Biodexa Pharmaceuticals (BDRX) Gross Margin (2015 - 2016) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 2 years of Gross Margin data on file, last reported at 168.39% in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 17.56 Bn | 17.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 168.39% |
| Dec 31, 2015 | 89.54% |